Opexa Therapeutics Inc (OPXA) Upgraded to "Buy" by Zacks Investment Research

Opexa Therapeutics Inc (OPXA) Upgraded to "Buy" by Zacks Investment Research


The firm presently has a $2.00 price target on the biopharmaceutical company's stock. Zacks Investment Research 's target price indicates a potential upside of 4.04% from the stock's current price.



from Biotech News